Investing in Pre-IPO Cannabis Companies
Our Next Pre-IPO Deal is Ready to Launch!
It happened last Monday.
One of our smaller Canadian cannabis stocks called THC Biomed (CSE: THC) hit $1.40, putting us up 1,066%.
While big gains are not uncommon in the legal cannabis space, this is the first gain in excess of 1,000% we’ve ever seen delivered inside of seven months.
That’s right, a 1,066% gain in just seven months. Check it out...
But I’m not telling you about this today to chest pound.
I’m telling you about this today because this won’t be the last gain in excess of 1,000% for us.
From Passion to Profits
If you’re a regular reader of these pages, you know I’m quite passionate about the legal cannabis market.
Not just because I think the war on drugs has been one of the worst tragedies ever to unfold in the United States — costing taxpayers more than $1 trillion while destroying the lives of millions of innocent people — but also because it can allow us to make a ridiculous amount of money while facilitating a necessary change.
Certainly I’ve been taking full advantage of this boom in cannabis stocks, and so have members of my Green Chip Stocks investment community.
Just take a look at some of these gains we’ve pulled off this year in the legal cannabis space:
- Aphria, Inc. (TSX-V: APH) — up 235.4%
- Canopy Growth Corporation (TSX: CGC) — up 316.25%
- Golden Leaf Holdings (CSE: GLH) — up 57.41%
- Mettrum Health (TSX-V: MT) — up 118.92%
- OrganiGram Holdings (TSX-V: OGI) — up 622.5%
And there’s plenty more to come, too.
Stay on top of the hottest investment ideas before they hit Wall Street. Sign up for the Wealth Daily newsletter below. You'll also get our free report, 3 Legal Marijuana Stocks to Own Now.
Big Pharma Loves Cannabis
Next month, a new legal cannabis company will be going public.
It’s a fully integrated health care and medical cannabis-based pharmaceutical company being led by a team of health care and pharmaceutical executives. That’s right, this is a Big Pharma play on cannabis. In fact, the company’s president is the former CEO of Purdue Pharma, one of the largest privately held pharmaceutical companies in the world, boasting annual revenues in excess of $3 billion.
But here’s the best part...
While the stock is certain to get a ton of market attention the day it goes public, members of Green Chip Stocks will be watching their shares of this company soar. Because, you see, members of Green Chip Stocks already own shares.
Because I’m able to get members of Green Chip Stocks in on pre-IPO deals, they get to cash in along with other high-net-worth investors, VC funds, and high-level CEOs.
Folks, this is how you get rich.
Buying shares of companies that are already trading publicly is fine. You can certainly build wealth that way. But going to the front of the line to get cheap shares of these companies before they go public? That’s how the Warren Buffetts of the world do it. And that’s how we do it, too.
Now, this particular pre-IPO opportunity is no longer available. The early money is already in, and now we’re looking forward to the launch of what will be another very hot cannabis stock.
But I’ve got plenty more to come.
In fact, in one more week, members of my Green Chip Stocks community will have yet another opportunity to invest in another early-stage deal that most investors will never even know about. We’ll be among the first to buy in, and we’ll be among the first to cash out.
Plain and simple: This is how we do things at Green Chip Stocks. So if you want to get in on this action, too, and get in our next deal, click here now.
To a new way of life and a new generation of wealth...
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially-responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.